Welcome to STN International! Enter x:x

LOGINID:ssspta1633cxq

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * *	* *	* *	* *	* Welcome to STN International * * * * * * *				
NEWS	1			Web Page for STN Seminar Schedule - N. America				
NEWS	2	APR	04	STN AnaVist, Version 1, to be discontinued				
NEWS	3	APR	15	WPIDS, WPINDEX, and WPIX enhanced with new				
				predefined hit display formats				
NEWS	. 4	APR	28	EMBASE Controlled Term thesaurus enhanced				
NEWS	5	APR	28	IMSRESEARCH reloaded with enhancements				
NEWS	6	MAY	30	INPAFAMDB now available on STN for patent family searching				
NEWS	7	MAY	30	DGENE, PCTGEN, and USGENE enhanced with new homology sequence search option				
NEWS	8	JUN	06	EPFULL enhanced with 260,000 English abstracts				
NEWS		JUN		KOREAPAT updated with 41,000 documents				
NEWS				USPATFULL and USPAT2 updated with 11-character				
				patent numbers for U.S. applications				
NEWS	11	JUN	19	CAS REGISTRY includes selected substances from web-based collections				
NEWS	12	JUN	25	CA/CAplus and USPAT databases updated with IPC reclassification data				
NEWS	13	JUN	30	AEROSPACE enhanced with more than 1 million U.S.				
				patent records				
NEWS	14	JUN	30	EMBASE, EMBAL, and LEMBASE updated with additional options to display authors and affiliated organizations				
NEWS	15	JUN	3.0	STN on the Web enhanced with new STN AnaVist				
MEMB	13	0 014	50	Assistant and BLAST plug-in				
NEWS	16	JUN	30	STN AnaVist enhanced with database content from				
EPFULI			- •					
NEWS	17	JUL	28	CA/CAplus patent coverage enhanced				
NEWS		JUL		EPFULL enhanced with additional legal status				
				information from the epoline Register				
NEWS	19	JUL	28	IFICDB, IFIPAT, and IFIUDB reloaded with				
enhancements								
NEWS	20	JUL	28	STN Viewer performance improved				
NEWS	21	AUG	01					
NEWS	22	AUG	13	CA/CAplus enhanced with printed Chemical Abstracts page images from 1967-1998				

NEWS 23 AUG 15 CAOLD to be discontinued on December 31, 2008

NEWS 24 AUG 15 CAplus currency for Korean patents enhanced

NEWS 25 AUG 25 CA/CAplus, CASREACT, and IFI and USPAT databases enhanced for more flexible patent number searching

NEWS 26 AUG 27 CAS definition of basic patents expanded to ensure comprehensive access to substance and sequence information

NEWS EXPRESS JUNE 27 08 CURRENT WINDOWS VERSION IS V8.3, AND CURRENT DISCOVER FILE IS DATED 23 JUNE 2008.

NEWS HOURS STN Operating Hours Plus Help Desk Availability NEWS LOGIN Welcome Banner and News Items

NEWS IPC8 For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

FILE 'HOME' ENTERED AT 19:11:33 ON 04 SEP 2008

=> FIL BIOSIS CAPLUS EMBASE COST IN U.S. DOLLARS

FULL ESTIMATED COST

SINCE FILE TOTAL ENTRY SESSION 0.21 0.21

FILE 'BIOSIS' ENTERED AT 19:11:50 ON 04 SEP 2008 Copyright (c) 2008 The Thomson Corporation

FILE 'CAPLUS' ENTERED AT 19:11:50 ON 04 SEP 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'EMBASE' ENTERED AT 19:11:50 ON 04 SEP 2008 Copyright (c) 2008 Elsevier B.V. All rights reserved.

=> s c myc

L1 43807 C MYC

=> s mRNA (3a) instabi?

L2 964 MRNA (3A) INSTABI?

```
=> s 11 and 12
            29 L1 AND L2
L3
=> dup rem 13
PROCESSING COMPLETED FOR L3
             15 DUP REM L3 (14 DUPLICATES REMOVED)
L4
=> d bib abs 1-
YOU HAVE REQUESTED DATA FROM 15 ANSWERS - CONTINUE? Y/(N):y
L4
    ANSWER 1 OF 15
                     CAPLUS
                            COPYRIGHT 2008 ACS on STN
AN
     2004:999715 CAPLUS
     141:406751
DN
TI
     Assay and expression systems comprising reporter gene and
instability
     sequence DNA for identifying compounds which affect stability of
mRNA
     Kastelic, Tania; Cheneval, Dominique
IN
     Novation Pharmaceuticals Inc., Can.
PA
     U.S. Pat. Appl. Publ., 49 pp., Cont.-in-part of U.S. Ser. No.
869,159.
     CODEN: USXXCO
DT
     Patent
LA
     English
FAN.CNT 2
                        KIND
                               DATE , APPLICATION NO.
     PATENT NO.
DATE
                                            .
                         ----
                                -----
                                           US 2004-814634
    US 20040231007
                                20041118
                         A1
20040401
     WO 2000039314
                         A1
                                20000706 WO 1999-CA1235
19991223
            AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN,
         W:
CR, CU,
             CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU,
ID, IL,
             IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU,
LV, MA,
             MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE,
SG, SI,
             SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA,
ZW
         RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH,
CY, DE,
             DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF,
BJ, CF,
             CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
                                20051013
                                           AU 2005-229165
     AU 2005229165
                         A1
20050401
     CA 2603585
                          A1
                                20051013 CA 2005-2603585
```

20050401

```
20051013
                                             WO 2005-CA491
                          A1
     WO 2005095615
20050401
             AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ,
         W:
CA, CH,
             CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI,
GB, GD,
             GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR,
KZ, LC,
             LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ,
NA, NI,
             NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK,
SL, SM,
             SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU,
ZA, ZM, ZW
         RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM,
ZW, AM,
             AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ,
DE, DK,
             EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL,
PL, PT,
             RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ,
GW, ML,
             MR, NE, SN, TD, TG
                                 20070418
                                             EP 2005-730094
     EP 1774000
                          A1
20050401
             AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR,
         R:
HU, IE,
             IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR
                                 20071101
                          Т
                                             JP 2007-505349
     JP 2007530058
20050401
                                 20070816
                                             US 2007-594851
     US 20070190532
                          A1
20070504
PRAI GB 1998-28709
                          Α
                                 19981224
     WO 1999-CA1235
                          W
                                 19991223
     US 2001-869159
                          A2
                                 20010815
     US 2004-814634
                          Α
                                 20040401
     WO 2005-CA491
                          W
                                 20050401
     The present invention relates to an assay for the identification
of biol.
```

active compds., in particular to a reporter gene assay for the identification of compds., which have an effect on mRNA stability. More

particularly, the present invention relates to a reporter gene expression

system and cell lines comprising said expression system. invention

further relates to compds. which destabilize mRNA. Radicicol and radicicol analog A showed a clear effect on mRNA stability. Human APP,

Bcl-2 α , c-myc, TNF α , IL-1 β , VEGF

instability sequence were constructed. Instability sequence DNA is from

The gene encoding a cytokine, a gene encoding a chemokine, a gene encoding

a nuclear transcription factor, a gene encoding an oxygenase, a proto-oncogene, an immediate early gene, a cell cycle controlling gene,

and a gene involved in apoptosis.

L4 ANSWER 2 OF 15 BIOSIS COPYRIGHT (c) 2008 The Thomson Corporation on STN

DUPLICATE 1

AN 2004:95192 BIOSIS

DN PREV200400084197

TI Mammary tumor induction in transgenic mice expressing an RNA-binding

protein.

AU Tessier, Charles R.; Doyle, Glenn A.; Clark, Brad A.; Pitot, Henry C.;

Ross, Jeff [Reprint Author]

CS McArdle Laboratory for Cancer Research, University of Wisconsin-Madison,

1400 University Avenue, Madison, WI, 53706, USA ross@oncology.wisc.edu

SO Cancer Research, (January 1 2004) Vol. 64, No. 1, pp. 209-214. print.

ISSN: 0008-5472 (ISSN print).

DT Article

LA English

ED Entered STN: 11 Feb 2004

Last Updated on STN: 11 Feb 2004

AB We have analyzed mammary tumors arising in transgenic mice expressing a

novel, multifunctional RNA-binding protein. The protein, which we call

the c-myc mRNA coding region

instability determinant binding protein (CRD-BP), binds to c-myc, insulin-like growth factor II, and beta-actin

mRNAs, and to H19 RNA. Depending on the RNA substrate, the CRD-BP affects

RNA localization, translation, or stability. CRD-BP levels are high

during fetal development but low or undetectable in normal adult tissues.

The CRD-BP is linked to tumorigenesis, because its expression is reactivated in some adult human breast, colon, and lung tumors. These

data suggest the CRD-BP is a proto-oncogene. To test this idea, the

CRD-BP was expressed from the whey acidic protein (WAP) promoter in

mammary epithelial cells of adult transgenic mice. The incidence of

mammary tumors was 95% and 60% in two lines of WAP-CRD-BP mice with high

and low relative CRD-BP expression, respectively. Some of the tumors

metastasized. Nontransgenic mice did not develop mammary tumors. H19 RNA

and insulin-like growth factor II mRNA were up-regulated significantly in

non-neoplastic WAP-CRD-BP mammary tissue. WAP-CRD-BP mice are a novel

 $\operatorname{\mathsf{model}}$ for $\operatorname{\mathsf{mammary}}$ neoplasia and $\operatorname{\mathsf{might}}$ provide insights into $\operatorname{\mathsf{human}}$ breast

cancer biology.

L4 ANSWER 3 OF 15 BIOSIS COPYRIGHT (c) 2008 The Thomson Corporation on STN

DUPLICATE 2

AN 2003:399109 BIOSIS

DN PREV200300399109

TI CRD-BP: A c-myc mRNA stabilizing protein with an oncofetal pattern of expression.

AU Ioannidis, P. [Reprint Author]; Mahaira, L.; Papadopoulou, A.; Teixeira,

M. R.; Heim, S.; Andersen, J. A.; Evangelou, E.; Dafni, U.; Pandis, N.;

Trangas, T.

CS Immunology Center, St Savvas Hospital, 171 Alexandras Ave, Athens, 11522,

Greece

pioannidis@ath.forthnet.gr

SO Anticancer Research, (May-June 2003) Vol. 23, No. 3A, pp. 2179-2184.

print.

CODEN: ANTRD4. ISSN: 0250-7005.

DT Article

General Review; (Literature Review)

LA English

ED Entered STN: 27 Aug 2003

Last Updated on STN: 27 Aug 2003

AB The Coding Region Determinant-Binding Protein (CRD-BP) is an RRM and

KH-domain-containing protein that recognizes specifically at least three

RNAs. It binds to one of the two c-myc mRNA instability elements, to the 5'Un Translated Region (UTR) of the leader 3 IGF-II mRNA and to the oncofetal H19 RNA. CRD-BP has been

assigned a role in stabilizing c-myc mRNA by

preventing its endonucleolytic cleavage and in repressing the translation

of the leader 3 IGF-II mRNA, the major embryonic species of this message.

CRD-BP is normally expressed only in fetal tissues. However, its expression is detected in primary tumors and transformed cell lines of

different origins. The vast majority of colon (80%) and breast (60%)

tumors and sarcomas (73%) express CRD-BP whereas in other tumor types, for

example prostate carcinomas, its expression is rare. CRD-BP expression

has also been detected in benign tumors such as breast fibroadenomas,

meningiomas and other benign mesenchymal tumors, implying a role for this

gene in abnormal cell proliferation. In breast carcinomas, CRD-BP

expression and or gene copy number gains in the region encompassing the

c-myc locus were detected in approximately 75% of tumors, implying that the deregulated expression of c-myc may be more widespread than previously believed. Infiltrated lymph nodes, corresponding to CRD-BP- positive primary tumors, were also

found positive indicating that monitoring for CRD-BP could prove useful

for the detection and monitoring of disseminated disease.

L4 ANSWER 4 OF 15 CAPLUS COPYRIGHT 2008 ACS on STN

AN 2002:430571 CAPLUS

DN 137:151401

TI Regulation of c-myc mRNA decay by translational pausing in a coding region instability determinant

AU Lemm, Ira; Ross, Jeff

CS McArdle Laboratory for Cancer Research, University of Wisconsin-Madison,

Madison, WI, 53706, USA

SO Molecular and Cellular Biology (2002), 22(12), 3959-3969 CODEN: MCEBD4; ISSN: 0270-7306

PB American Society for Microbiology

DT Journal

LA English

AB A 249-nucleotide coding region instability determinant (CRD) destabilizes

c-myc mRNA. Previous expts. identified a CRD-binding protein (CRD-BP) that appears to protect the CRD from endonuclease

cleavage. However, it was unclear why a CRD-BP is required to protect a

well-translated mRNA whose coding region is covered with ribosomes. We

hypothesized that translational pausing in the CRD generates a ribosome-deficient region downstream of the pause site, and this region is

exposed to endonuclease attack unless it is shielded by the

Transfection and cell-free translation expts. reported here support this

hypothesis. Ribosome pausing occurs within the c-myc CRD in tRNA-depleted reticulocyte translation reactions. The pause sites

map to a rare arginine (CGA) codon and to an adjacent threonine (ACA)

codon. Changing these codons to more common codons increases translational efficiency in vitro and increases mRNA abundance in transfected cells. These data suggest that c-myc mRNA

is rapidly degraded unless it is (i) translated without pausing or (ii)

protected by the CRD-BP when pausing occurs. Addnl. mapping expts.

suggest that the CRD is bipartite, with several upstream translation pause

sites and a downstream endonuclease cleavage site.

RE.CNT 65 THERE ARE 65 CITED REFERENCES AVAILABLE FOR THIS RECORD ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 5 OF 15 BIOSIS COPYRIGHT (c) 2008 The Thomson Corporation on STN

AN 2002:308512 BIOSIS

DN PREV200200308512

TI Correlation between intrinsic mRNA stability and the affinity of AUF1

(hnRNP D) and HuR for A+U-rich mRNAs.

AU Blaxall, Burns C.; Pende, Aldo; Wu, Steven C.; Port, J. David [Reprint

authorl

CS Division of Cardiology, University of Colorado HSC, 4200 East Ninth

Avenue, B139, Denver, CO, 80262, USA david.port@uchsc.edu

SO Molecular and Cellular Biochemistry, (March, 2002) Vol. 232, No. 1-2, pp.

1-11. print.

CODEN: MCBIB8. ISSN: 0300-8177.

DT Article

LA English

ED Entered STN: 22 May 2002

Last Updated on STN: 22 May 2002

AB Presence of A+U-rich elements (AREs) within 3'-untranslated regions

(3'UTRs) of numerous mRNAs has been associated with rapid mRNA turnover;

however, the interaction of specific factors with AREs is also associated

with mRNA stabilization. Recently, two ARE binding proteins with putative

mRNA destabilizing (AUF1) and stabilizing (HuR) properties have been

described. However, no direct comparison of AUF1 and HuR binding properties has been made. Therefore, we examined the relative affinities

of p37AUF1 and HuR for a diverse set of ARE-containing mRNAs encoding

beta-adrenergic receptors, a proto-oncogene, and a cytokine. We find that

high-affinity AUF1 binding appears to require elements beyond primary

nucleotide sequence. In contrast, binding of HuR appears considerably

less constrained. As a functional correlate, we determined the ability of

these specific mRNA sequences to affect the stability of chimeric beta-globin mRNA constructs. Although the relative affinity of AUF1 and

HuR are generally predictive of mRNA stability, we find that certain mRNA

sequences do not conform to these generalizations.

L4 ANSWER 6 OF 15 BIOSIS COPYRIGHT (c) 2008 The Thomson Corporation on STN

DUPLICATE 3

AN 2001:313891 BIOSIS

DN PREV200100313891

TI mRNA localization by a 145-nucleotide region of the c-fos 3'-untranslated

region: Links to translation but not stability.

AU Dalgleish, Gillian; Veyrune, Jean-Luc; Blanchard, Jean-Marie; Hesketh,

John [Reprint author]

CS Rowett Research Institute, Bucksburn, Aberdeen, AB21 9SB, UK j.e.hesketh@ncl.ac.uk

SO Journal of Biological Chemistry, (April 27, 2001) Vol. 276, No. 17, pp.

13593-13599. print.

CODEN: JBCHA3. ISSN: 0021-9258.

DT Article

LA English

ED Entered STN: 4 Jul 2001

Last Updated on STN: 19 Feb 2002

AB The presence of a localization signal in the 3'-untranslated region of

c-fos mRNA was investigated by in situ hybridization and cell fractionation techniques. Cells were transfected with chimeric gene

constructs in which the beta-globin coding region was used as a reporter

and linked to either its own 3'-untranslated region, the c-fos 3'-untranslated region, or the c-fos 3'-untranslated region containing

different deletions. Replacement of the endogenous beta-globin 3'-untranslated region by that from c-fos caused a redistribution of the

transcripts so that they were recovered in cytoskeletal-bound polysomes

and seen localized in the perinuclear cytoplasm. Deletion of the AU-rich

instability region did not affect transcript localization, but removal of

a distinct 145-nucleotide region of the 3'-untranslated region abolished

it. The prevention of transcript translation by desferrioxamine led to a

marked loss of transcript localization, independent of mRNA instability. The data show that the 3'-untranslated region of c-fos mRNA, as c-myc, contains a localization signal,

which targets the mRNA to the perinuclear cytoskeleton. We propose that

this is important to ensure efficient nuclear import of these key regulatory proteins. mRNA localization by the fos 3'-untranslated region

is independent of mRNA instability, and the two are determined by different regulatory elements.

L4 ANSWER 7 OF 15 BIOSIS COPYRIGHT (c) 2008 The Thomson Corporation on STN

DUPLICATE 4

AN 1997:226015 BIOSIS

DN PREV199799517731

TI Identification of two proteins that bind to a pyrimidine-rich sequence in

the 3'-untranslated region of GAP-43 mRNA.

AU Irwin, Nina [Reprint author]; Baekelandt, Veerle; Goritchenko, Luda;

Benowitz, Larry I.

CS Lab. Neurosci. Res. Neurosurg., Children's Hosp., En 308, 300 Longwood

Ave., Boston, MA 02115, USA

SO Nucleic Acids Research, (1997) Vol. 25, No. 6, pp. 1281-1288. CODEN: NARHAD. ISSN: 0305-1048.

DT Article

LA English

To

ED Entered STN: 22 May 1997

Last Updated on STN: 22 May 1997

AB GAP-43 is a membrane phosphoprotein that is important for the development

and plasticity of neural connections. In undifferentiated PC12 pheochromocytoma cells, GAP-43 mRNA degrades rapidly (t-1/2, = 5 h), but

becomes stable when cells are treated with nerve growth factor.

identify trans-acting factors that may influence mRNA stability, we

combined column chromatography and gel mobility shift assays to isolate

GAP-43 mRNA binding proteins from neonatal bovine brain tissue. This

resulted in the isolation of two proteins that bind specifically and

competitively to a pyrimidine-rich sequence in the 3'-untranslated region

of GAP-43 mRNA. Partial amino acid sequencing revealed that one of the

RNA binding proteins coincides with FBP (far upstream element binding

protein), previously characterized as a protein that resembles hnRNP K and

which binds to a single-stranded, pyrimidine-rich DNA sequence upstream of

the c-myc gene to activate its expression. The other binding protein shares sequence homology with PTB, a polypyrimidine tract

binding protein implicated in RNA splicing and regulation of translation

initiation. The two proteins bind to a 26 nt pyrimidine-rich sequence

lying 300 nt downstream of the end of the coding region, in an area shown

by others to confer instability on a reporter mRNA in

transient transfection assays. We therefore propose that FBP and the

PTB-like protein may compete for binding at the same site to influence the

stability of GAP-43 mRNA.

L4 ANSWER 8 OF 15 BIOSIS COPYRIGHT (c) 2008 The Thomson Corporation on STN

DUPLICATE 5

AN 1996:364403 BIOSIS

DN PREV199699086759

TI Identification of sequences in c-myc mRNA that regulate its steady-state levels.

AU Yeilding, Newman M.; Rehman, Muhammad T.; Lee, William M. F. [Reprint

author]

CS 663 CRB, 415 Curie Blvd., Univ. Pennsylvania, Philadelphia, PA 19104, USA

SO Molecular and Cellular Biology, (1996) Vol. 16, No. 7, pp. 3511-3522.

CODEN: MCEBD4. ISSN: 0270-7306.

DT Article

LA English

ED Entered STN: 14 Aug 1996

Last Updated on STN: 14 Aug 1996

AB The level of cellular myc proto-oncogene expression is rapidly regulated

in response to environmental signals and influences cell proliferation and

differentiation. Regulation is dependent on the fast turnover of

c-myc mRNA, which enables cells to rapidly alter

c-myc mRNA levels. Efforts to identify elements in myc

mRNA responsible for its instability have used a variety

of approaches, all of which require manipulations that perturb normal cell

metabolism. These various approaches have implicated different regions of

the mRNA and have led to a lack of consensus over which regions actually

dictate rapid turnover and low steady-state levels of cmyc mRNA. To identify these regions by an approach that does not perturb cell metabolism acutely and that directly assesses the effect of a

c-myc mRNA region on the steady-state levels of

c-myc mRNA, we developed an assay using reverse

transcription and PCR to compare the steady-state levels of human myc

mRNAs transcribed from two similarly constructed myc genes transiently

cotransfected into proliferating C2C12 myoblasts. Deletion mutations were

introduced into myc genes, and the levels of their mRNAs were compared

with that of a near-normal, reference myc mRNA. Deletion of most of the

myc 3' untranslated region (UTR) raised myc mRNA levels, while deletion of

sequences in the myc 5' UTR (most of exon 1), exon 2, or the protein-coding region of exon 3 did not, thus demonstrating that the 3'

UTR is responsible for keeping myc mRNA levels low. Using a similar

reverse transcription-PCR assay for comparing the steady-state levels of

two beta-globin-myc fusion mRNAs, we showed that fusion of the myc 3' UTR

lowers globin mRNA levels by destabilizing beta-globin mRNA.
Surprisingly, fusion of the protein-coding region of myc exon 3
also

lowered globin mRNA steady-state levels. Investigating the possibility

that exon 3 coding sequences may play some other role in regulating

c-myc mRNA turnover, we demonstrated that these sequences, but not myc 3' UTR sequences, are necessary for the normal

posttranscriptional downregulation of c-myc mRNA during myoblast differentiation. We conclude that, while two elements

within c-myc mRNA can act as

instability determinants in a heterologous context, only the
 instability element in the 3' UTR regulates its steady-state
levels in

proliferating C2C12 cells.

ANSWER 9 OF 15 EMBASE COPYRIGHT (c) 2008 Elsevier B.V. All L4rights reserved on STN AN 1995141433 EMBASE Expression of the blood-clotting factor-VIII cDNA is repressed TI by a transcriptional silencer located in its coding region. Hoeben, Rob C., Dr. (correspondence) AU CS Lab. of Molecular Carcinogenesis, Department of Medical Biochemistry, Sylvius Laboratory, Wassenaarseweg 72, 2333 AL Leiden, Netherlands. Fallaux, Frits J.; Cramer, Steve J.; Van Den Wollenberg, Diana J.M.; Van Ormondt, Hans; Briet, Ernest; Van Der Eb, Alex J. SO Blood, (1 May 1995) Vol. 85, No. 9, pp. 2447-2454. Refs: 39 ISSN: 0006-4971 CODEN: BLOOAW United States CY DTJournal; Article FS 022 Human Genetics 025 Hematology 005 General Pathology and Pathological Anatomy English LA SL English ED Entered STN: 31 May 1995 Last Updated on STN: 31 May 1995 Hemophilia A is caused by a deficiency of factor-VIII AB procoagulant (fVIII) The current treatment by frequent infusions of activity. plasma-derived fVIII concentrates is very effective but has the risk of transmittance of blood- borne viruses (human immunodeficiency virus [H/V], hepatitis viruses). Use of recombinant DNA-derived fVIII as well as gene therapy could make hemophilia treatment independent of blood-derived products. far, the problematic production of the fVIII protein and the low titers of the fVIII retrovirus stocks have prevented preclinical trials of gene therapy for hemophilia A in large-animal models. We have initiated a study of the mechanisms that oppose efficient fVIII synthesis.

established that fVIII cDNA contains sequences that dominantly inhibit its

We have

own expression from retroviral as well as from plasmid vectors. The

inhibition is not caused by instability of the fVIII mRNA (t(1/2), ± 6 hours) but rather to repression at the level of transcription. A 305-bp fragment is identified that is involved in but

not sufficient for repression. This fragment does not overlap the region

recently identified by Lynch et al (Hum Gene Ther 4:259, 1993) as a

dominant inhibitor of RNA accumulation. The repression is mediated by a

cellular factor (or factors) and is independent of the orientation of the

element in the transcription unit, giving the repressor element the

hallmarks of a transcriptional silencer.

L4 ANSWER 10 OF 15 BIOSIS COPYRIGHT (c) 2008 The Thomson Corporation on

STN DUPLICATE 6

AN 1993:209797 BIOSIS

DN PREV199395111022

TI 1,25-Dihydroxyvitamin D-3 destabilizes c-myc mRNA in HL-60 leukemic cells.

AU Mangasarian, Karen; Mellon, William S. [Reprint author]

CS University Wisconsin, School Pharmacy, 425 N. Charter St.,

Madison, WI

53706, USA

SO Biochimica et Biophysica Acta, (1993) Vol. 1172, No. 1-2, pp. 55-63.

CODEN: BBACAQ. ISSN: 0006-3002.

DT Article

LA English

ED Entered STN: 23 Apr 1993 Last Updated on STN: 23 Apr 1993

AB The differentiation process is accompanied by alterations in the expression of a variety of genes. Monocytic maturation of hematopoietic

cells (HL-60) induced by 1,25-dihydroxyvitamin D-3 (1,25(OH)-2D-3),

results in a decrease in steady state c-myc mRNA

levels. To elucidate the mechanism by which $1,25\,\mathrm{(OH)}\,\mathrm{-2D}\mathrm{-3}$ regulates

c-myc mRNA expression, transcriptional and

post-transcriptional modes of regulation were investigated. No transcriptional regulation was identified, however,

1,25(OH)-2D-3 appeared

to decrease steady state c-myc mRNA levels by

increasing its turnover rate. Using actinomycin D to block transcription,

the half-life of c-myc mRNA was shown to decrease from 20 min in the absence of 1,25(OH)-2D-3 to lt 5 min in the presence of

1,25(OH)-2D-3. Cycloheximide reversed the instability induced by 1,25(OH)-2D-3, prolonging the half-life of c-myc mRNA

in both uninduced and 1,25(OH)-2D-3-induced HL60 cells to gt 60 min,

indicating a translational requirement for the destabilization process.

Additionally, the c-myc mRNA

instability induced by 1,25(OH)-2D-3 in HL-60 appears to be a specific result of this agent, as indicated by the inability of other

monocytic and granulocytic differentiation inducing agents to destabilize

c-myc mRNA.

L4 ANSWER 11 OF 15 CAPLUS COPYRIGHT 2008 ACS on STN

AN 1992:230257 CAPLUS

DN 116:230257

OREF 116:38859a,38862a

TI What determines the instability of c-myc proto-oncogene mRNA?

AU Laird-Offringa, Ite A.

CS Dep. Microbiol. Mol. Genet., Harvard Med. Sch., Boston, MA, 02115, USA

SO BioEssays (1992), 14(2), 119-24 CODEN: BIOEEJ; ISSN: 0265-9247

DT Journal; General Review

LA English

the

AB A review with 38 refs. on the mechanism of degradation of c-myc mRNA, and its similarity with c-fos mRNA decay. The c-myc proto-oncogene is believed to be involved in the regulation of cell growth and differentiation. Deregulation of this gene, resulting

in an inappropriate increase of gene product, can contribute to cancer

formation. One of the ways in which the expression of the c-myc gene can be deregulated is by the stabilization of the labile c-myc mRNA. The rapid degradation of the c-

myc transcripts appears to be mediated by at least 2 distinct regions in the mRNA. One lies in the 3' untranslated region, and presumably consists of (A+U)-rich sequences. The other lies in

C-terminal part of the coding region and colocalizes with sequences

encoding protein-dimerization motifs. The exact mechanism by which the

destabilizing elements function is not yet clear. Shortening of the

poly(A) tail of the c-myc message appears to precede degradation of the transcript. When translation is blocked, this shortening

is slowed down and the mRNA is stabilized. This suggests that deadenylation is required before degradation of the mRNA body can take place.

L4 ANSWER 12 OF 15 BIOSIS COPYRIGHT (c) 2008 The Thomson Corporation on

STN DUPLICATE 7

AN 1991:340854 BIOSIS

DN PREV199192040229; BA92:40229

TI RAPID C-MYC MESSENGER RNA DEGRADATION DOES NOT REQUIRE A PLUS U-RICH SEQUENCES OR COMPLETE TRANSLATION OF THE MESSENGER RNA.

AU LAIRD-OFFRINGA I A [Reprint author]; ELFFERICH P; VAN DER EB A J CS DEP MICROBIOL MOL GENET, HARVARD MED SCH, 200 LONGWOOD AVE, BOSTON, MASS

02115, USA

SO Nucleic Acids Research, (1991) Vol. 19, No. 9, pp. 2387-2394. CODEN: NARHAD. ISSN: 0305-1048.

DT Article

FS BA

LA ENGLISH

ED Entered STN: 31 Jul 1991 Last Updated on STN: 1 Aug 1991

AB The c-myc proto-oncogene encodes a highly unstable mRNA. Stabilized, turncated myc transcripts have been found in several

human and murine tumors of hematopoietic origin. Recently, two tumors

expressing 3' truncated c-myc mRNAs that were five times more stable than normal myc transcripts, were described.

tried to determine the cause of the increased stability of the 3' truncated myc transcripts by studying the half-life of mutated c -myc mRNAs. The c-myc 3' untranslated

region has been shown to contain sequences that confer mRNA instability. Possible candidates for such sequences are two (A + U)-rich regions in the 3' end of the c-myc RNA that

resemble RNA destabilizing elements present in the c-fos and GMCSF mRNAs.

We show that deletions in the (A + U)-rich regions do not stabilize

c-myc messengers, and that hybrid mRNAs containing SV40
sequences at their 3' ends and terminating at an SV40
polyadenylation

signal decay as quickly as normal c-myc transcripts. Our results indicate that neither the loss of (A + U)-rich sequences nor

the mere addition of non-myc sequences to the 3' end of the mRNA lead to

stabilization. We also show that rapid degradation of c-myc mRNA does not require complete translation of the coding sequences.

L4 ANSWER 13 OF 15 CAPLUS COPYRIGHT 2008 ACS on STN AN 1991:56810 CAPLUS

```
DN
     114:56810
OREF 114:9641a,9644a
     Cis-acting determinants required for c-myc
     mRNA instability and their mechanistic implications
ΑU
     Mango, Susan Elizabeth
     Princeton Univ., Princeton, NJ, USA
CS
     (1990) 133 pp. Avail.: Univ. Microfilms Int., Order No.
SO
DA9027580
     From: Diss. Abstr. Int. B 1990, 51(5), 2209-10
DT
     Dissertation
LΑ
     English
    Unavailable
AB
L4
    ANSWER 14 OF 15 CAPLUS COPYRIGHT 2008 ACS on STN
    1989:52215 CAPLUS
AN
DN
     110:52215
OREF 110:8517a,8520a
     Activation of the transforming potential of the human fos
proto-oncogene
     requires message stabilization and results in increased amounts
of
     partially modified fos protein
     Lee, William M. F.; Lin, Chin; Curran, Tom
ΑU
     Cancer Res. Inst., Univ. California, San Francisco, CA, 94143,
CS
USA
     Molecular and Cellular Biology (1988), 8(12), 5521-7
SO
     CODEN: MCEBD4; ISSN: 0270-7306
DT
     Journal
LA
     English
AB
     The requirements for activation of the transformation potential
of the
     human c-fos proto-oncogene were investigated. Recombinant
plasmids containing
     the Moloney murine leukemia virus long terminal repeat directing
     transcription of the c-fos coding region and either the
authentic c-fos 3'
     untranslated region (UTR) or the 3' UTR from human c-myc
     were inefficient at inducing transformation. In contrast, a
recombinant
     that substituted most of the c-fos 3' UTR with the 3' portion of
the
     simian virus 40 T-antigen gene transformed cells well.
difference in
     transformation efficiency appeared to be due to significantly
higher
     levels of fos mRNA and protein expressed from the transforming
     recombinant.
                  This, in turn, was due to the much greater
stability of its
     mRNA compared with those from the poorly transforming
recombinants containing
```

the c-fos or c-myc 3' UTR. Thus, the 3' UTR of the

limits the

human c-fos mRNA is responsible for its rapid degradation and

steady-state levels of transcript and protein. Cells transformed by the

activated human c-fos plasmids contained increased amts. of partially

modified c-fos protein (c-Fos). This form of c-fos turned over much more

rapidly than the highly modified form of c-fos induced by serum stimulation.

L4 ANSWER 15 OF 15 CAPLUS COPYRIGHT 2008 ACS on STN

AN 1985:22195 CAPLUS

DN 102:22195

OREF 102:3645a,3648a

TI Extreme instability of myc mRNA in normal and transformed human cells

AU Dani, C.; Blanchard, J. M.; Piechaczyk, M.; El Sabouty, S.; Marty, L.;

Jeanteur, P.

CS Lab. Biol. Mol., Univ. Sci. Tech. Languedoc, Montpellier, 34060, Fr.

SO Proceedings of the National Academy of Sciences of the United States of

America (1984), 81(22), 7046-50 CODEN: PNASA6; ISSN: 0027-8424

DT Journal

LA English

AB To address the possibility that the expression of the myc gene might be

regulated at a post-transcriptional level, the half-life of myc mRNA in

various cells was investigated. The survey included normal human embryonic fibroblasts as well as transformed human cells of various

origins: cervix carcinoma (HeLa), breast carcinoma (MCF7), Burkitt

lymphoma (Daudi), and promyelocytic leukemia (HL60). All these cells

revealed an extreme instability of myc mRNA

(half-life, .apprx.10 min), suggesting that the control of myc mRNA

degradation might be a general means (although not necessarily exclusive) of

regulating both the level and the timing of myc gene expression.

Inhibition of protein synthesis resulted in a dramatic

stabilization of

myc mRNA in HeLa, MCF7, and HL60 cells, suggesting that the controlling

element might itself be, at least in these cells, a protein of rapid

turnover. This finding opens the way to studying the mechanism of myc

mRNA inactivation in these different cell types. However, protein

synthesis inhibition had no effect on myc mRNA instability in other transformed (Daudi) cells lines as well as normal embryonic human fibroblasts. These different types of behavior

suggest that the post-transcriptional control of myc gene expression might .

involve multiple factors that would be differently affected in various \cdot

cell types.

=> FIL STNGUIDE

COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	51.57	51.78
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-4.00	SESSION

-4.00

FILE 'STNGUIDE' ENTERED AT 19:14:15 ON 04 SEP 2008 USE IS SUBJECT TO THE TERMS OF YOUR CUSTOMER AGREEMENT COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

FILE CONTAINS CURRENT INFORMATION.
LAST RELOADED: Aug 29, 2008 (20080829/UP).

=>

---Logging off of STN---

=>

Executing the logoff script...

=> LOG Y

COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	0.18	51.96
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE	TOTAL
	ENTRY	SESSION
CA SUBSCRIBER PRICE -4.00	0.00	

STN INTERNATIONAL LOGOFF AT 19:16:04 ON 04 SEP 2008